Docoh
Loading...

DHR Danaher

Danaher Corporation is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 69,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.

Company profile

Ticker
DHR, DHR+A, DHR+B
Exchange
Website
CEO
Rainer Blair
Employees
Incorporated
Fiscal year end
Former names
DMG INC
SEC CIK
Subsidiaries
AB Sciex Germany GmbH • AB Sciex LLC • AB Sciex LP • AB Sciex Pte Ltd. • Applitek NV • Aquatic Infomatics ULC • BC Distribution BV • Beckman Coulter Australia Pty Ltd • Beckman Coulter Biotechnology (Suzhou) Co. Ltd. • Beckman Coulter Biyomedikal Urunler Sanayi ve Ticaret Limited ...
IRS number
591995548

DHR stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

21 Jul 21
23 Sep 21
31 Dec 21
Quarter (USD)
Jul 21 Apr 21 Dec 20 Oct 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Danaher earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Aug 21 Raskas Daniel Common Stock Gift Dispose G No No 0 306 0 22,244
13 Aug 21 Lutz Robert S Common Stock Sell Dispose S No No 313.947 1,761 552.86K 16,155
13 Aug 21 Lutz Robert S Common Stock Sell Dispose S No No 313.103 3,239 1.01M 17,916
13 Aug 21 Lutz Robert S Common Stock Option exercise Acquire M No No 57.9 5,000 289.5K 21,155
13 Aug 21 Lutz Robert S Employee Stock Option Danaher Corporation Option exercise Dispose M No No 57.9 5,000 289.5K 14,847
30 Jul 21 Weidemanis Joakim Common Stock Sell Dispose S No No 298.928 6,700 2M 70,720
30 Jul 21 Spoon Alan G Phantom shares Common Stock Grant Acquire A No No 297.49 138.796 41.29K 24,140.597
30 Jul 21 List-Stoll Teri Phantom Shares Common Stock Grant Acquire A No No 297.49 109.506 32.58K 6,426.988

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

77.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1761 1731 +1.7%
Opened positions 147 115 +27.8%
Closed positions 117 126 -7.1%
Increased positions 654 655 -0.2%
Reduced positions 675 693 -2.6%
13F shares
Current Prev Q Change
Total value 148.4B 124.32B +19.4%
Total shares 552.85M 552.56M +0.1%
Total puts 2.52M 1.58M +59.4%
Total calls 2.38M 1.84M +29.1%
Total put/call ratio 1.1 0.9 +23.4%
Largest owners
Shares Value Change
Vanguard 49.37M $13.25B +0.6%
BLK Blackrock 44.26M $11.88B -2.5%
TROW T. Rowe Price 31.98M $8.58B -0.5%
FMR 28.6M $7.68B +0.3%
STT State Street 25.21M $6.77B +1.7%
Wellington Management 19.24M $5.16B -7.7%
Massachusetts Financial Services 14.08M $3.78B -5.1%
MS Morgan Stanley 13.73M $3.68B +0.4%
BAC Bank Of America 11.1M $2.98B +3.1%
Geode Capital Management 10.02M $2.68B +1.3%
Largest transactions
Shares Bought/sold Change
Amundi 3.94M +3.94M NEW
Amundi Pioneer Asset Management 0 -3.46M EXIT
Wellington Management 19.24M -1.6M -7.7%
Brown Advisory 3.74M -1.21M -24.4%
BLK Blackrock 44.26M -1.12M -2.5%
Manufacturers Life Insurance Company, The 3.24M +1.05M +47.7%
Citadel Advisors 639.08K -923.61K -59.1%
1832 Asset Management 1.75M +841.87K +92.9%
WDR Waddell & Reed Financial 0 -804.72K EXIT
Massachusetts Financial Services 14.08M -752.13K -5.1%

Financial report summary

?
Risks
  • The COVID-19 pandemic has adversely impacted, and continues to pose risks to, certain elements of our business and our financial statements, the nature and extent of which are highly uncertain and unpredictable.
  • We face intense competition and if we are unable to compete effectively, we may experience decreased demand and decreased market share. Even if we compete effectively, we may be required to reduce the prices we charge.
  • Our growth depends in part on the timely development and commercialization, and customer acceptance, of new and enhanced products and services based on technological innovation.
  • The health care industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes in an effort to reduce (and increase the predictability of) costs, which can adversely affect our business and financial statements.
  • International economic, political, legal, compliance, social and business factors can negatively affect our business and financial statements.
  • Our growth can suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality.
  • Certain of our businesses rely on relationships with collaborative partners and other third-parties for development, supply and marketing of certain products, potential products and technologies, and such collaborative partners or other third-parties could fail to perform sufficiently.
  • Any inability to consummate acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price.
  • Our acquisition of businesses, investments, joint ventures and other strategic relationships could negatively impact our business and financial statements.
  • The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities.
  • Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we or our predecessors have disposed could adversely affect our business and financial statements.
  • Potential indemnification liabilities pursuant to the Communications Disposition, the Fortive Disposition or the Envista Disposition could materially and adversely affect our business and financial statements.
  • We could incur significant liability if any of the Communications Disposition, the Fortive Disposition or the Envista Disposition is determined to be a taxable transaction.
  • A significant disruption in, or breach in security of, our information technology systems or data or violation of data privacy laws can adversely affect our business and financial statements.
  • Defects and unanticipated use or inadequate disclosure with respect to our products or services, or allegations thereof, can adversely affect our business and financial statements.
  • If we suffer loss to our facilities, supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed.
  • The manufacture of many of our products is a highly exacting and complex process, and if we directly or indirectly encounter problems manufacturing products, our business and financial statements could suffer.
  • If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes in market conditions and customer demand, our business and financial statements may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services can cause production interruptions, delays and inefficiencies.
  • Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns or inventory levels of, key distributors and other channel partners can adversely affect our business and financial statements.
  • Our financial results are subject to fluctuations in the cost and availability of commodities that we use in our operations.
  • Our restructuring actions can have long-term adverse effects on our business and financial statements.
  • Work stoppages, union and works council campaigns and other labor disputes could adversely impact our productivity and results of operations.
  • If we are unable to adequately protect our intellectual property, or if third-parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights. These risks are particularly pronounced in countries in which we do business that do not have levels of protection of intellectual property comparable to the United States.
  • Third-parties from time to time claim that we are infringing or misappropriating their intellectual property rights and we could suffer significant litigation expenses, losses or licensing expenses or be prevented from selling products or services.
  • The U.S. government has certain rights to use and disclose some of the intellectual property that we license and could exclusively license it to a third-party if we fail to achieve practical application of the intellectual property.
  • Our outstanding debt has increased significantly as a result of the Cytiva Acquisition, and we may incur additional debt in the future. Our existing and future indebtedness may limit our operations and our use of our cash flow and negatively impact our credit ratings; and any failure to comply with the covenants that apply to our indebtedness could adversely affect our business and financial statements.
  • We may be required to recognize impairment charges for our goodwill and other intangible assets.
  • Foreign currency exchange rates can adversely affect our financial statements.
  • Changes in our tax rates or exposure to additional income tax liabilities or assessments can affect our profitability. In addition, audits by tax authorities can result in additional tax payments for prior periods.
  • Changes in tax law relating to multinational corporations could adversely affect our tax position.
  • Legal, political, and economic uncertainty surrounding the exit of the United Kingdom (“UK”) from the EU could have an adverse effect on our business and financial statements.
  • Our defined benefit pension plans are subject to financial market risks that could adversely affect our financial statements.
  • Significant developments or changes in U.S. laws or policies, including changes in U.S. trade policies and tariffs and the reaction of other countries thereto, particularly China, can have an adverse effect on our business and financial statements.
  • Our business and financial statements can be impaired by improper conduct by any of our employees, agents or business partners.
  • Our businesses are subject to extensive regulation; failure to comply with those regulations could adversely affect our business and financial statements.
  • We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in the course of our business that can adversely affect our business and financial statements.
  • Certain of our businesses are subject to extensive regulation by the U.S. FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our business and financial statements.
  • Our products are subject to clinical trials, the results of which may be unexpected, or perceived as unfavorable by the market, and could adversely affect our business and financial statements.
  • Off-label marketing of our products could result in substantial penalties.
  • Certain modifications to our products may require new 510(k) clearances or other marketing authorizations and may require us to recall or cease marketing our products.
  • Our operations, products and services expose us to the risk of environmental, health and safety liabilities, costs and violations that could adversely affect our business and financial statements.
  • Changes in governmental regulations can reduce demand for our products or services or increase our expenses.
Management Discussion
  • In this report, references to the non-GAAP measures of core sales (also referred to as core revenues or sales/revenues from existing businesses) and core sales including Cytiva refer to sales calculated according to U.S. GAAP, but excluding:
  • •the impact of currency translation.
  • References to sales or operating profit attributable to acquisitions or acquired businesses refer to sales or operating profit, as applicable, from acquired businesses recorded prior to the first anniversary of the acquisition less the amount of sales and operating profit, as applicable, attributable to divested product lines not considered discontinued operations prior to the first anniversary of the divestiture; provided that in calculating core sales including Cytiva, Cytiva’s sales (net of the sales of the Company product lines divested in 2020 to obtain regulatory approval to acquire Cytiva, or the “divested product lines”) (“Cytiva sales”) are excluded from the definition of sales attributable to acquisitions or acquired businesses. The portion of revenue attributable to currency translation is calculated as the difference between:
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
Coll freshman Bad
New words: administered, Aldevron, behalf, biotechnology, blocked, Department, DNA, enabling, encryption, FSB, Human, incident, Iran, jointly, knowingly, medicine, mRNA, OFAC, ordinarily, petroleum, plasmid, proportion, rata, receipt, Russia, Russian, Syria
Removed: cancellation, Envista, exemption, formally, implemented, laboratory, moderated, Notwithstanding, physical, produce, reflecting, registration, resume, shutdown, strength

Patents

APP
Utility
Chromatography Ligand Comprising Domain C from Staphylococcus Aureus Protein a for Antibody Isolation
23 Sep 21
The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof.
APP
Utility
Biological Sample Treatment Apparatus
23 Sep 21
An apparatus for treating biological samples disposed on substrates, including: an input buffer for receiving one or more substrate holders each being adapted to support a plurality of the substrates; a treatment zone including a plurality of treatment stations each being adapted to receive one of the substrates; a reagent dispenser configured by a controller to dispense reagents to the substrates at the treatment stations; a substrate transport device configured by the controller to transport individual substrates between the substrate holders in the input buffer and the treatment stations.
APP
Utility
Storage Vial
23 Sep 21
A storage vial (100, 200) may include a vial body (110, 210) having a first end (111, 211) and a second end (112, 212) and defining an internal volume (113, 213) configured to contain a biological material (B) therein, a first valve (120, 220) positioned at the first end of the vial body, a second valve (130, 230) positioned at the second end of the vial body, a first conduit connector (160, 260) positioned at the first end of the vial body, and a second conduit connector (170, 270) positioned at the second end of the vial body.
APP
Utility
Method for Adenovirus Purification
23 Sep 21
The present invention relates to a method for virus purification.
GRANT
Design
Reagent cassette
21 Sep 21
Inventors: Paul Darbyshire, Maxim Stanislaw Pamieta, Mark Wilcock